Targeting PI3K/Akt/mTOR signaling in cancer

Camillo Porta, Chiara Paglino, Alessandra Mosca

Research output: Contribution to journalArticlepeer-review


The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling pathways are two pathways crucial to many aspects of cell growth and survival, in physiological as well as in pathological conditions (e.g., cancer). Indeed, they are so interconnected that, in a certain sense, they could be regarded as a single, unique pathway. In this paper, after a general overview of the biological significance and the main components of these pathways, we address the present status of the development of specific PI3K, Akt, and mTOR inhibitors, from already registered medicines to novel compounds that are just leaving the laboratory bench.

Original languageEnglish
Article numberArticle 64
JournalFrontiers in Oncology
Volume4 APR
Publication statusPublished - 2014


  • Akt
  • Everolimus
  • Inhibitors
  • MTOR
  • Novel agents
  • PI3K
  • Ridaforolimus
  • Temsirolimus

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Targeting PI3K/Akt/mTOR signaling in cancer'. Together they form a unique fingerprint.

Cite this